Clinical Trial: Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07396324) titled 'Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer' on Feb. 01.

Brief Summary: This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Intervention: DRUG: Iparomlimab and Tuvonralimab (QL1706)

5.0mg/kg qw, sta...